These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1545 related items for PubMed ID: 21085046

  • 1. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P, Kara T, Kara Gedik G, Kara F, Sahin O, Ceylan Gunay E, Sari O.
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [Abstract] [Full Text] [Related]

  • 2. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, Kuwabara M, Yagyu Y, Kumano S, Imaoka I, Tsuchiya N, Ashikaga R, Hosono M, Murakami T.
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [Abstract] [Full Text] [Related]

  • 3. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX, Cheng J, Xu WG, Dai D, Song XY, Ma WC, Zhu L, Zhu X.
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E, Turgut B, Cakmakcilar A, Erturk SA.
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [Abstract] [Full Text] [Related]

  • 5. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
    Watanabe H, Kanematsu M, Goshima S, Kondo H, Kawada H, Noda Y, Moriyama N.
    Ann Nucl Med; 2013 Aug; 27(7):648-53. PubMed ID: 23625579
    [Abstract] [Full Text] [Related]

  • 6. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
    Boland GW, Blake MA, Holalkere NS, Hahn PF.
    AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
    [Abstract] [Full Text] [Related]

  • 7. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
    Koopman D, van Dalen JA, Stigt JA, Slump CH, Knollema S, Jager PL.
    Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
    [Abstract] [Full Text] [Related]

  • 8. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI, Cheon GJ, Paeng JC, Cho JY, Kang KW, Chung JK, Kim EE, Lee DS.
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [Abstract] [Full Text] [Related]

  • 9. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy--initial experience.
    Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman AJ, Mueller PR, Boland GW.
    Radiology; 2006 Mar; 238(3):970-7. PubMed ID: 16505394
    [Abstract] [Full Text] [Related]

  • 10. Role of 18F-FDG PET/CT in the differential diagnosis of primary benign and malignant unilateral adrenal tumors.
    Ma G, Zhang X, Wang M, Xu X, Xu B, Guan Z.
    Quant Imaging Med Surg; 2021 May; 11(5):2013-2018. PubMed ID: 33936982
    [Abstract] [Full Text] [Related]

  • 11. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M, Erba P, Volterrani D, Guidoccio F, Lazzeri E, Caramella D, Mariani G.
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [Abstract] [Full Text] [Related]

  • 12. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N, Sharma P, Soundararajan R, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.
    Diagn Interv Radiol; 2013 Jul; 19(4):294-8. PubMed ID: 23439252
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic performance of 18-F-FDG-PET-CT in adrenal lesions using histopathology as reference standard.
    Altinmakas E, Hobbs BP, Ye H, Grubbs EG, Perrier ND, Prieto VG, Lee JE, Ng CS.
    Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
    [Abstract] [Full Text] [Related]

  • 14. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
    Brady MJ, Thomas J, Wong TZ, Franklin KM, Ho LM, Paulson EK.
    Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
    [Abstract] [Full Text] [Related]

  • 15. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J, Matyskiel R, Toutounchi S, Grabowska-Derlatka L, Koperski L, Królicki L.
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [Abstract] [Full Text] [Related]

  • 16. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
    Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S.
    J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
    [Abstract] [Full Text] [Related]

  • 17. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
    Chae EY, Cha JH, Kim HH, Shin HJ, Kim HJ, Oh HY, Koh YH, Moon DH.
    Acta Radiol; 2012 Jun 01; 53(5):530-5. PubMed ID: 22593124
    [Abstract] [Full Text] [Related]

  • 18. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR.
    Clin Radiol; 2008 Jul 01; 63(7):756-64. PubMed ID: 18555033
    [Abstract] [Full Text] [Related]

  • 19. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R, Kido S, Suga K, Hirano Y, Tachibana R, Muramatsu K, Chagawa K, Tanaka S.
    Ann Nucl Med; 2014 Nov 01; 28(9):926-35. PubMed ID: 25107363
    [Abstract] [Full Text] [Related]

  • 20. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
    Nakajo M, Jinguji M, Fukukura Y, Kajiya Y, Tani A, Nakajo M, Nakabeppu Y, Arimura H, Nishio Y, Nakamura F, Yoshiura T.
    Eur Radiol; 2015 Dec 01; 25(12):3696-705. PubMed ID: 25925356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.